voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
Company profile
Ticker
VYGR
Exchange
Website
CEO
G. Andre Turenne
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
VYGR stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
Other Events
13 Mar 24
S-8
Registration of securities for employees
28 Feb 24
8-K
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
D
$20.00 mm in equity, sold $20.00 mm, 1 investor
17 Jan 24
8-K
Voyager Therapeutics Announces Pricing of Public Offering
8 Jan 24
424B5
Prospectus supplement for primary offering
8 Jan 24
424B5
Prospectus supplement for primary offering
4 Jan 24
8-K
Entry into a Material Definitive Agreement
2 Jan 24
Transcripts
VYGR
Earnings call transcript
2023 Q4
28 Feb 24
VYGR
Earnings call transcript
2023 Q3
6 Nov 23
VYGR
Earnings call transcript
2023 Q2
3 Aug 23
VYGR
Earnings call transcript
2023 Q1
9 May 23
VYGR
Earnings call transcript
2022 Q4
7 Mar 23
VYGR
Earnings call transcript
2022 Q3
8 Nov 22
VYGR
Earnings call transcript
2022 Q2
6 Aug 22
VYGR
Earnings call transcript
2021 Q4
8 Mar 22
VYGR
Earnings call transcript
2020 Q4
26 Feb 21
VYGR
Earnings call transcript
2019 Q4
3 Mar 20
Latest ownership filings
4
Toby Ferguson
3 Apr 24
4
Robin Swartz
3 Apr 24
4
Alfred Sandrock
3 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
4
Toby Ferguson
26 Mar 24
3
Toby Ferguson
26 Mar 24
4
Robin Swartz
22 Feb 24
4
Alfred Sandrock
22 Feb 24
4
PETER P. PFREUNDSCHUH
22 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 66.86 mm | 66.86 mm | 66.86 mm | 66.86 mm | 66.86 mm | 66.86 mm |
Cash burn (monthly) | 59.67 mm | 2.63 mm | 9.84 mm | (no burn) | 7.02 mm | (no burn) |
Cash used (since last report) | 407.78 mm | 17.94 mm | 67.21 mm | n/a | 47.95 mm | n/a |
Cash remaining | -340.91 mm | 48.92 mm | -348.37 k | n/a | 18.91 mm | n/a |
Runway (months of cash) | -5.7 | 18.6 | -0.0 | n/a | 2.7 | n/a |
Institutional ownership, Q2 2023
73.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 107 |
Opened positions | 42 |
Closed positions | 18 |
Increased positions | 36 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 282.43 bn |
Total shares | 39.82 mm |
Total puts | 36.80 k |
Total calls | 72.30 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
NBIX Neurocrine Biosciences | 8.58 mm | $59.34 mm |
Third Rock Ventures III | 5.43 mm | $0.00 |
EcoR1 Capital | 3.85 mm | $44.10 bn |
Armistice Capital | 3.62 mm | $41.49 bn |
BLK Blackrock | 2.48 mm | $28.37 bn |
Vanguard | 2.48 mm | $28.35 bn |
Farallon Capital Management | 1.29 mm | $14.79 bn |
T. Rowe Price | 1.23 mm | $14.08 bn |
D. E. Shaw & Co. | 947.97 k | $10.85 bn |
MS Morgan Stanley | 783.07 k | $8.97 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Alfred Sandrock | Common Stock | Sell | Dispose S | No | No | 9.86 | 12,115 | 119.45 k | 322,839 |
2 Apr 24 | Robin Swartz | Common Stock | Sell | Dispose S | No | No | 9.88 | 1,357 | 13.41 k | 117,004 |
1 Apr 24 | Toby Ferguson | Common Stock | Grant | Acquire A | No | No | 0 | 105,000 | 0.00 | 105,000 |
25 Mar 24 | Toby Ferguson | Stock Option Common Stock | Grant | Acquire A | No | No | 9.26 | 210,000 | 1.94 mm | 210,000 |
News
Guggenheim Initiates Coverage On Voyager Therapeutics with Buy Rating, Announces Price Target of $22
26 Mar 24
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
19 Mar 24
HC Wainwright & Co. Initiates Coverage On Voyager Therapeutics with Buy Rating, Announces Price Target of $30
19 Mar 24
Citigroup Initiates Coverage On Voyager Therapeutics with Buy Rating, Announces Price Target of $16
7 Mar 24
Tech Stocks Set To Rise Thursday As January Inflation Data Fails To Scare Markets, Small Caps Surge
29 Feb 24
Press releases
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
16 Apr 24
NorthStar Appoints Peter Pfreundschuh to Board of Managers
15 Apr 24
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26 Mar 24
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
13 Mar 24
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
28 Feb 24